Originally published as JCO Early Release 10.1200/JCO.2006.09.7535 on July 2 2007
Journal of Clinical Oncology, Vol 25, No 23 (August 10), 2007: pp. 3415-3420
© 2007 American Society of Clinical Oncology.
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy
Henri Roché,
Louise Yelle,
Francesco Cognetti,
Louis Mauriac,
Craig Bunnell,
Joseph Sparano,
Pierre Kerbrat,
Jean-Pierre Delord,
Linda Vahdat,
Ronald Peck,
David Lebwohl,
Rana Ezzeddine,
Hervé Curé
From the Institut Claudius Regaud, Toulouse; Institut Bergonie, Bordeaux; Centre Eugene Marquis, Rennes; Centre Jean Perrin, Clermont-Ferrand, France; Centre Hospitalier de l'Université de Montréal–Hôpital Notre-Dame, Montreal, Quebec, Canada; Comitato Etico (Istituto di Ricovero e Cura a Carattere Scientifico) di Roma, IFO-Istituto Regina Elena, Rome, Italy; Dana-Farber Cancer Institute, Boston, MA; Albert Einstein Comprehensive Cancer Center, Montefiore Medical Center, Department of Oncology; Weill Medical College of Cornell University, New York, NY; and Bristol-Myers Squibb, Wallingford, CT
Address reprint requests to Henri Roché, MD, Institut Claudius Regaud, 20-24 rue du Saint Pierre, 31052 Toulouse Cedex, France; e-mail: roche.henri{at}claudiusregaud.fr
Purpose There is a need for new agents to treat metastatic breast cancer (MBC) in patients for whom anthracycline therapy has failed or is contraindicated. This study was conducted to assess the efficacy and safety of the novel antineoplastic, the epothilone B analog ixabepilone, in patients with MBC previously treated with an adjuvant anthracycline.
Patients and Methods Patients were age  18 years and had received a prior anthracycline-based regimen as adjuvant treatment. Ixabepilone as first-line metastatic chemotherapy was administered as a 40 mg/m2 intravenous infusion during 3 hours every 3 weeks. The primary efficacy end point was objective response rate (ORR). Secondary efficacy end points included duration of response, time to response, time to progression, and survival.
Results All 65 patients were assessable for response. Their median age was 52 years (range, 33 to 80 years). ORR was 41.5% (95% CI, 29.4% to 54.4%), median duration of response was 8.2 months (95% CI, 5.7 to 10.2 months), and median time to response was 6 weeks (range, 5 to 17 weeks). Median survival was 22.0 months (95% CI, 15.6 to 27.0 months). Treatment-related adverse events were manageable and mostly grades 1/2: the most common of these (other than alopecia) was mild to moderate neuropathy, which was primarily sensory and mostly reversible in nature.
Conclusion Ixabepilone is efficacious and has a predictable and manageable safety profile in women with MBC previously treated with an adjuvant anthracycline.
published online ahead of print at www.jco.org on July 31, 2006.
Supported by Bristol-Myers Squibb Co.
Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, May 18-21, 2002, Orlando, FL; 39th Annual Meeting of the American Society of Clinical Oncology, May 31-June 3, 2003, Chicago, IL; International Union Against Cancer Meeting, 2006; and Roché H, Perez E, Llombart-Cussac A, et al: Ixabepilone, an epothilone analog, is effective in ER-, PR-, HER2-negative (triple-negative) patients: data from neoadjuvant and metastatic breast cancer trials. Ann Oncol 17:ix93-ix113, 2006 (abstr 256-P).
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Editorial
- Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs
Luca Gianni
JCO 2007 25: 3389-3391
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
L. T. Vahdat, B. Pruitt, C. J. Fabian, R. R. Rivera, D. A. Smith, E. Tan-Chiu, J. Wright, A. R. Tan, N. A. DaCosta, E. Chuang, et al.
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
J. Clin. Oncol.,
June 20, 2009;
27(18):
2954 - 2961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Boehnke Michaud
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer
Journal of Oncology Pharmacy Practice,
June 1, 2009;
15(2):
95 - 106.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc.,
June 1, 2009;
84(6):
533 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Yardley
Proactive Management of Adverse Events Maintains the Clinical Benefit of Ixabepilone
Oncologist,
May 1, 2009;
14(5):
448 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Baselga, M. Zambetti, A. Llombart-Cussac, G. Manikhas, E. Kubista, G. G. Steger, A. Makhson, S. Tjulandin, H. Ludwig, M. Verrill, et al.
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
J. Clin. Oncol.,
February 1, 2009;
27(4):
526 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Widemann, W. Goodspeed, A. Goodwin, T. Fojo, F. M. Balis, and E. Fox
Phase I Trial and Pharmacokinetic Study of Ixabepilone Administered Daily for 5 Days in Children and Adolescents With Refractory Solid Tumors
J. Clin. Oncol.,
February 1, 2009;
27(4):
550 - 556.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Dumontet, M. A. Jordan, and F. F.Y. Lee
Ixabepilone: targeting {beta}III-tubulin expression in taxane-resistant malignancies
Mol. Cancer Ther.,
January 1, 2009;
8(1):
17 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Plummer, P. Woll, D. Fyfe, A. V. Boddy, M. Griffin, P. Hewitt, J. Carmichael, F. Namouni, M. Cohen, and M. Verrill
A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
Clin. Cancer Res.,
December 15, 2008;
14(24):
8288 - 8294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goel, G. L. Goldberg, D. Y.-S. Kuo, F. Muggia, J. Arezzo, and S. Mani
Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone
Ann. Onc.,
December 1, 2008;
19(12):
2048 - 2052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rivera, J. Lee, and A. Davies
Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors
Oncologist,
December 1, 2008;
13(12):
1207 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Morris and M. N. Fornier
Microtubule Active Agents: Beyond the Taxane Frontier
Clin. Cancer Res.,
November 15, 2008;
14(22):
7167 - 7172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goodin
Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer
Am. J. Health Syst. Pharm.,
November 1, 2008;
65(21):
2017 - 2026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Tan and D. L. Toppmeyer
Ixabepilone in Metastatic Breast Cancer: Complement or Alternative to Taxanes?
Clin. Cancer Res.,
November 1, 2008;
14(21):
6725 - 6729.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhushan and C. M Walko
Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer
Ann. Pharmacother.,
September 1, 2008;
42(9):
1252 - 1261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goodin
Novel cytotoxic agents: Epothilones
Am. J. Health Syst. Pharm.,
May 15, 2008;
65(10_Supplement_3):
S10 - S15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Lee and S. M. Swain
The Epothilones: Translating from the Laboratory to the Clinic
Clin. Cancer Res.,
March 15, 2008;
14(6):
1618 - 1624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Vahdat
Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms
Oncologist,
March 1, 2008;
13(3):
214 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The Epothilones Are Coming!
Journal Watch Oncology and Hematology,
August 28, 2007;
2007(828):
1 - 1.
[Full Text]
|
|
|
|
|
|
|
L. Gianni
Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs
J. Clin. Oncol.,
August 10, 2007;
25(23):
3389 - 3391.
[Full Text]
[PDF]
|
|
|
|
